1. Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13).
- Author
-
Weichenhan D, Riedel A, Sollier E, Toprak UH, Hey J, Breuer K, Wierzbinska JA, Touzart A, Lutsik P, Bähr M, Östlund A, Nilsson T, Jacobsson S, Edler M, Waraky A, Behrens YL, Göhring G, Schlegelberger B, Steinek C, Harz H, Leonhardt H, Dolnik A, Reinhardt D, Bullinger L, Palmqvist L, Lipka DB, and Plass C
- Subjects
- Humans, Child, Gene Expression Regulation, Leukemic, Child, Preschool, ETS Translocation Variant 6 Protein, Repressor Proteins genetics, Repressor Proteins metabolism, Male, Proto-Oncogene Proteins c-ets genetics, Proto-Oncogene Proteins c-ets metabolism, Infant, Female, Adolescent, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, Transcription Factors genetics, Transcription Factors metabolism, Homeodomain Proteins genetics, Homeodomain Proteins metabolism, Translocation, Genetic, Promoter Regions, Genetic, Chromosomes, Human, Pair 7 genetics, Enhancer Elements, Genetic
- Abstract
Abstract: Acute myeloid leukemia (AML) with the t(7;12)(q36;p13) translocation occurs only in very young children and has a poor clinical outcome. The expected oncofusion between break point partners (motor neuron and pancreas homeobox 1 [MNX1] and ETS variant transcription factor 6 [ETV6]) has only been reported in a subset of cases. However, a universal feature is the strong transcript and protein expression of MNX1, a homeobox transcription factor that is normally not expressed in hematopoietic cells. Here, we map the translocation break points on chromosomes 7 and 12 in affected patients to a region proximal to MNX1 and either introns 1 or 2 of ETV6. The frequency of MNX1 overexpression in pediatric AML is 2.4% and occurs predominantly in t(7;12)(q36;p13) AML. Chromatin interaction assays in a t(7;12)(q36;p13) induced pluripotent stem cell line model unravel an enhancer-hijacking event that explains MNX1 overexpression in hematopoietic cells. Our data suggest that enhancer hijacking may be a more widespread consequence of translocations in which no oncofusion product was identified, including t(1;3) or t(4;12) AML., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF